Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | TTR | P02766 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17522786 | 0.81 | TTR (0.77) | SMN1; SMN2LMNATTRMEN1KMT2A | |
| SCHEMBL19801746 | 0.81 | TTR (0.84) | SMN1; SMN2LMNATTRMEN1KMT2A | |
| SCHEMBL17522781 | 0.81 | TTR (0.64) | SMN1; SMN2LMNATTRMEN1KMT2A | |
| SCHEMBL17495600 | 0.79 | TTR (0.56) | SMN1; SMN2LMNATTRMEN1KMT2A | |
| SCHEMBL4229319 | 0.79 | AR (1.00) | LMNATTRMEN1KMT2AAR | |
| SCHEMBL17522785 | 0.78 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNATTRMEN1KMT2A | |
| SCHEMBL17522791 | 0.78 | TTR (0.94) | SMN1; SMN2LMNATTRMEN1KMT2A | |
| SCHEMBL2469151 | 0.77 | MAPT (0.89) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL5054312 | 0.75 | MAPT (0.85) | SMN1; SMN2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL22610055 | 0.75 | SMN1; SMN2 (0.88) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | MAHA THERAPEUTICS, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | MAHA THERAPEUTICS, INC. | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045609-A1 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE | TTR, TTPA, SERPINA6 | SMN1; SMN2 1239/4885LMNA 1031/4885TTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.